Cell and Gene Therapy’s Next Phase: From Regulatory Flexibility to Scalable Delivery
Cell and gene therapy has moved beyond scientific promise into a more demanding execution phase. Regulators are signaling greater flexibility, investors are watching commercialization more carefully, and patients are waiting for therapies that can move through complex manufacturing and delivery pathways without breaking down.
For billion-dollar-plus life sciences and biotech CEOs, the central issue is no longer whether the science is transformative. The issue is whether the operating model can move individualized, complex, time-sensitive therapies from development to commercial delivery at scale.
Regulatory flexibility may open the path, but scalable delivery will determine who creates value.
Regulatory Flexibility Is Raising Expectations
In January 2026, FDA announced a more flexible approach to overseeing chemistry, manufacturing, and control requirements for cell and gene therapies. FDA stated that the approach is intended to help expedite development and guide evaluation of development strategies ahead of Biologics License Application submissions. The agency also noted that CBER has approved close to 50 cell and gene therapies over the last decade.
That flexibility is important. Cell and gene therapies are frequently individualized, manufactured in small batches, dependent on specialized analytical methods, and constrained by time-sensitive logistics. Traditional expectations designed for large-scale, uniform manufacturing do not always fit the operational reality of these products.
But flexibility does not eliminate rigor. FDA’s guidance makes clear that sponsors must still control quality, justify manufacturing changes, manage comparability, and leverage prior knowledge appropriately. The bar is not lower; it is more tailored. That makes execution discipline even more important.
The Pipeline Is Expanding Faster Than Delivery Systems
The cell and gene therapy pipeline continues to grow. ASGCT’s 2026 Q1 landscape report reported 41 gene therapy trials initiated in the quarter and 1,915 open gene therapy clinical trials. The Alliance for Regenerative Medicine’s Q1 2026 snapshot also highlighted continuing commercialization momentum, including multiple therapies that crossed blockbuster revenue thresholds in 2025.
These signals point to a sector moving from early validation toward broader adoption. Yet commercial delivery remains difficult. Unlike many traditional products, cell and gene therapies often require treatment-center qualification, patient-specific manufacturing slots, cryogenic logistics, chain-of-identity controls, payer authorization, scheduling coordination, and post-treatment monitoring.
Every handoff is a potential failure point. A therapy can have compelling clinical value and still underperform commercially if the enterprise cannot reliably coordinate patients, sites, manufacturing, logistics, reimbursement, and follow-up.
CMC Readiness Is Becoming a Strategic Constraint
For cell and gene therapy companies, CMC readiness cannot be treated as a late-stage technical function. It is a strategic constraint that affects clinical development, regulatory timing, patient access, cost of goods, partner diligence, and commercial scalability.
FDA’s CMC flexibilities guidance emphasizes use of prior knowledge, lifecycle-based validation, and limited comparability data in certain low-risk situations. These flexibilities can reduce unnecessary burden, but they require strong internal control. Companies must know which methods, specifications, release tests, stability assumptions, and process parameters are defensible across development stages.
This creates a practical CEO challenge: the organization must build enough structure to scale without slowing innovation. Too little control creates regulatory and quality risk. Too much rigidity can delay development and make small-population therapies economically infeasible. The advantage belongs to companies that can manage that balance deliberately.
Commercial Scale Is Built Long Before Launch
Many cell and gene therapy companies underestimate how early commercial execution must begin. Treatment-center onboarding, field education, payer access, patient identification, logistics planning, quality release, and pharmacovigilance requirements cannot be assembled at the end of development without creating risk. By the time approval approaches, the operating model is already either ready or fragile.
The launch challenge is also different from traditional biopharma. A small number of high-value patients can create intense operational pressure because every case matters. A delayed slot, missed shipment, incomplete authorization, late test result, or underprepared site can affect patient access, revenue recognition, physician confidence, and brand credibility.
For CEOs, scalable delivery requires an enterprise view of readiness. Clinical, medical, market access, manufacturing, quality, supply chain, patient services, finance, and field teams must operate from the same launch assumptions. If demand forecasts, site capacity, manufacturing slots, and reimbursement workflows are developed separately, the company will discover gaps only when the system is under pressure.
The most advanced organizations build a “case flow” view of the business: how a patient moves from identification to eligibility, authorization, collection, manufacturing, release, infusion, follow-up, billing, and monitoring. That view exposes bottlenecks that traditional functional reporting often misses and allows leadership to improve the system before launch volumes rise.
The Margin Question Is Becoming More Important
As more cell and gene therapies move toward commercial markets, CEOs must also face the economics of delivery. High clinical value does not automatically translate into attractive operating performance if manufacturing yield is unstable, quality release is delayed, sites are underprepared, or patient support processes are too manual to scale.
The cost structure can be unforgiving. Small-batch manufacturing, specialized labor, complex logistics, treatment-center support, reimbursement assistance, and post-treatment monitoring can all add cost before revenue is fully realized. The operating model must therefore be designed to protect both access and margin, especially as payers and health systems become more experienced in evaluating these therapies.
Leaders should look beyond the approval event and ask whether the business can scale with a repeatable cost-to-serve model. That includes knowing where automation, standardization, partner control, and process redesign can reduce friction without compromising safety or quality.
Scalable Delivery Requires End-to-End Operating Control
Commercial delivery in cell and gene therapy does not begin at approval. It begins when the company designs the development, manufacturing, and access model. Decisions made during clinical development affect site readiness, manufacturing slotting, supply chain architecture, reimbursement pathways, field support, and patient experience after launch.
This is why the next phase of the sector will separate scientific leaders from enterprise operators. The companies that scale will be those that can translate regulatory flexibility into controlled execution: clear treatment pathways, reliable scheduling, robust chain-of-custody systems, disciplined partner governance, and operating cadence across clinical, manufacturing, quality, regulatory, market access, and commercial teams.
For CEOs, the question is not only how many therapies can be advanced. It is whether the company can build a repeatable delivery model that preserves safety, quality, margin, and patient access as volume grows.
The Brooks International Perspective
From Brooks International’s perspective, cell and gene therapy’s next phase is an execution-system challenge. Scientific breakthroughs will not reach their full value if the organization cannot control the operating complexity between development and patient delivery.
The most important opportunities often sit at the intersections: CMC and clinical operations, treatment centers and manufacturing slots, payer authorization and patient scheduling, quality release and logistics, regulatory strategy and commercial readiness. If those interfaces are not governed, the therapy may be promising but the enterprise will remain fragile.
Brooks International helps leadership teams build the management routines, accountability structure, and operating visibility required to turn complex therapy delivery into repeatable performance. The objective is not to over-bureaucratize innovation. It is to make scale possible without losing control.
The goal is to create a management system that can follow each therapy from scientific promise to patient delivery. That means making operating dependencies visible, establishing clear ownership across functions, and managing launch readiness as a live enterprise system rather than a checklist.
What Life Sciences & Biotech Leaders Should Be Asking Now
The leadership agenda should test whether the company can convert regulatory flexibility into scalable delivery.
• Where are the most material handoff risks across clinical operations, manufacturing, quality release, logistics, and treatment centers?
• Does the company have a clear CMC roadmap that supports the next regulatory, financing, and commercial milestones?
• Are treatment-center readiness, payer authorization, patient scheduling, and manufacturing capacity managed as one operating system?
• Can leadership see early indicators of slot constraints, release delays, comparability issues, or chain-of-custody risk?
• Are external partners governed through clear performance expectations, escalation routines, and decision rights?
• Does the launch model protect patient experience, clinical quality, and financial performance as volumes increase?
The Leadership Imperative
Cell and gene therapy has entered a stage where regulatory flexibility and scientific progress must be matched by operating maturity.
That requires leadership to manage cell and gene therapy as an integrated enterprise system, not a sequence of functional handoffs. The organizations that build that system early will be better positioned to absorb demand, protect quality, support treatment sites, and convert regulatory momentum into durable commercial performance.
The winners will not simply be the companies with the most advanced platforms. They will be the organizations that can coordinate complex manufacturing, regulatory expectations, partner networks, treatment sites, and patient access with precision.
For life sciences and biotech leaders, the mandate is clear: build delivery capability before demand exposes the gaps.
